Publication date: Oct 14, 2024
The aim of this study was to explore the clinical characteristics of patients infected with different Omicron subvariants presenting non-severe disease, evaluate the safety and efficacy of Azvudine for treatment of COVID-19, in order to broaden understanding of Omicron subvariant infections. A total of 244 individuals with Omicron subvariant (BA. 2.76, n = 158; BA. 5.1, n = 86) were included in the study. Demographic, clinical, and laboratory data of the study participants were collected and analyzed. Patients infected with BA. 5.1 exhibited a higher incidence of clinical symptoms like fatigue (25. 58% vs. 2. 53%, p
Open Access PDF
| Concepts | Keywords |
|---|---|
| China | Azvudine |
| Demographic | BA.2.76 |
| Fatigue | BA.5.1 |
| Laboratory | clinical features |
| nucleic acid negativization | |
| omicron subvariant | |
| pneumonia |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | infections |
| disease | MESH | COVID-19 |
| disease | MESH | Liver Diseases |
| disease | MESH | Rare Diseases |
| disease | MESH | Infectious Diseases |
| disease | MESH | virus shedding |
| disease | IDO | blood |
| disease | IDO | cell |
| disease | IDO | nucleic acid |
| disease | IDO | infection |
| disease | MESH | pneumonia |
| disease | MESH | dyspnea |
| drug | DRUGBANK | Coenzyme M |
| pathway | REACTOME | Reproduction |
| disease | IDO | infectivity |
| disease | IDO | symptom |
| disease | MESH | febrile seizure |
| disease | MESH | syndrome |
| disease | IDO | protein |
| disease | IDO | replication |
| disease | MESH | inflammation |
| disease | MESH | viral load |
| disease | MESH | Hypertension |
| disease | MESH | tumor |
Original Article
(Visited 2 times, 1 visits today)